Vertex Pharmaceuticals
VRTX
1,519 hedge funds and large institutions have $90.8B invested in Vertex Pharmaceuticals in 2025 Q3 according to their latest regulatory filings, with 143 funds opening new positions, 550 increasing their positions, 617 reducing their positions, and 156 closing their positions.
59% more call options, than puts
Call options by funds: $846M | Put options by funds: $533M
8% less first-time investments, than exits
New positions opened: 143 | Existing positions closed: 156
3% less funds holding
Funds holding: 1,559 → 1,519 (-40)
3.23% less ownership
Funds ownership: 93.81% → 90.59% (-3.2%)
11% less repeat investments, than reductions
Existing positions increased: 550 | Existing positions reduced: 617
15% less capital invested
Capital invested by funds: $107B → $90.8B (-$16.4B)
56% less funds holding in top 10
Funds holding in top 10: 16 → 7 (-9)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Capital International Investors
Los Angeles,
California
|
+$858M |
| 2 |
ClearBridge Investments
New York
|
+$467M |
| 3 |
JP Morgan Chase
New York
|
+$236M |
| 4 |
Assenagon Asset Management
Senningerberg,
Luxembourg
|
+$218M |
| 5 |
Capital Research Global Investors
Los Angeles,
California
|
+$186M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
-$1.3B |
| 2 |
Capital World Investors
Los Angeles,
California
|
-$1.18B |
| 3 |
Jennison Associates
New York
|
-$1.13B |
| 4 |
Edgewood Management
Greenwich,
Connecticut
|
-$404M |
| 5 |
Massachusetts Financial Services
Boston,
Massachusetts
|
-$326M |
VRTX Hedge Fund Activity: Q3 2025 in Review
1,519 of the 7,620 institutional investors tracked by Wall St. Rank reported a position in Vertex Pharmaceuticals (VRTX) for Q3 2025, worth a combined $90.8B — down 15% from $107B a quarter earlier.
Sellers outnumbered buyers: 156 funds closed out of VRTX and 143 opened new positions — a net loss of 13 holders — while 617 trimmed existing stakes and 550 added.
The largest buyer was Capital International Investors, adding an estimated $858M. The largest seller was Fidelity Investments, cutting an estimated $1.3B.
- 1,519 institutional investors held Vertex Pharmaceuticals (VRTX) as of Q3 2025, down from 1,559 in Q2 2025.
- Funds reported $90.8B of Vertex Pharmaceuticals stock for Q3 2025, down 15% quarter-over-quarter.
- 143 funds opened new Vertex Pharmaceuticals positions in Q3 2025 and 156 closed out, a net change of -13 holders.
- The largest Vertex Pharmaceuticals buyer in Q3 2025 was Capital International Investors, an estimated $858M added.
- The largest Vertex Pharmaceuticals seller in Q3 2025 was Fidelity Investments, an estimated $1.3B sold.
Based on aggregated 13F filings for Q3 2025.